In the 4T1 cohort, CCL11, a chemokine also known as Eotaxin that selectively recruits eosinophils and is associated with increased immune cell infiltration in breast cancer [44], was significantly higher in the combination treatment group than in IgG isotype controls (p = 0.0161) (Fig. 9C). The gene discussed is CCL11; the disease is breast carcinoma.